CORONA Remedies Ltd commissions additional capacity

CORONA Remedies Limited has successfully commenced the additional commercial production of tablet(s) / capsule(s) at the Bhayla manufacturing facility (Facility) of the Company. As on March 31, 2025, the Facility has an installed capacity of 852.80 million with the available capacity of 600 million and actual production of 561.49 million which is equivalent to capacity utilization of 93.58%. The additional production will raise the installed capacity by 400 million and available capacity by 240 million at the Facility.

The additional commercial production commenced with effect from Monday, December 22, 2025 at approximately 10:00 a.m.

The additional commercial production will add a significant milestone in the Company's strategic expansion to augment the upcoming market demands, enhance the in-house production capabilities and improve the supply chain agility.

The commercialized additional capacity is entirely being funded through internal accruals.

Shares of CORONA Remedies Limited was last trading in BSE at Rs. 1356.65 as compared to the previous close of Rs. 1374.85. The total number of shares traded during the day was 50607 in over 3142 trades.

The stock hit an intraday high of Rs. 1391.05 and intraday low of 1345.35. The net turnover during the day was Rs. 69382973.00.

Source : Equity Bulls

Keywords

CORONARemedies INE02ZQ01018 Pharmaceuticals Expansion AdditionalCapacity CommercialProduction Bhayla